OmniScience and INmune Bio Partner for Alzheimer’s Trial
By Karen Roman OmniScience and INmune Bio, Inc. (Nasdaq: INMB) said they’re using genAI in an Alzheimer’s disease trial. The AI will support the live clinical trial and is expected to increase efficiency and the probability of success, both companies...